4 Stocks You'll Wish You Bought on This Dip (One Is Down Over 50%)

Market analysts are currently identifying significant opportunities for investors to "buy the dip," particularly in stocks that have recently experienced declines despite strong earnings potential. Alec Green, chief investment strategist at the Oxford Club, highlights a concentrated market led by a few major players, which has left many other stocks undervalued. He emphasizes that while the top eight stocks in the S&P 500 account for over 35% of the index's market capitalization, there are still numerous mid-cap, large-cap, and international stocks with promising growth prospects.

Green points to several catalysts that could drive stock prices higher, including the upcoming midterm elections, which historically lead to a "midterm miracle" effect, resulting in significant market gains in the months following the elections. He also notes the solid economic backdrop, full employment, and exceptional profit growth forecasts, with third-quarter profit growth expected to reach 30%. This combination of factors suggests that share prices are likely to follow earnings upward.

Among the stocks Green recommends is Mercado Libre, often referred to as the "Amazon of Latin America," which has seen its stock price falter despite strong long-term growth prospects. He also discusses Novo Nordisk, a pharmaceutical company known for its GLP-1 obesity treatment, which has potential for significant market expansion despite recent earnings misses. Additionally, Tyler Technologies, a software firm focused on improving government efficiency, is highlighted for its stable earnings and growth potential.

Lastly, Green mentions Summit Technologies, a speculative biotech company with a promising lung cancer drug awaiting FDA approval. He advises caution with this stock, suggesting investors consider a trailing stop strategy to manage risk while capitalizing on potential short-term gains. Overall, Green's insights provide a roadmap for investors looking to navigate the current market landscape and identify undervalued opportunities.

Get the FREE Phase Two AI Report of the next AI stocks most of the market isn't paying attention to yet: https://www.marketbeat.com/y/yt1028/

Buying the dip is one of the oldest ways to build wealth in the stock market... and right now there are a lot of chances to do it. Alexander Green, Chief Investment Strategist at the Oxford Club, joins MarketBeat with four buy the dip stocks to buy now, all trading well below their highs.

Alexander explains why so much of the market is chasing the same handful of mega cap stocks, and why the best opportunities may be in the other 492 stocks in the S&P 500, in small cap stocks and in international stocks. He also breaks down what money manager Ken Fisher calls the "midterm miracle." Over the last 100 years, the nine months after the midterm elections have been the strongest nine months for the stock market, with an average gain of 19.5%... no matter who wins.

His list covers the leader in Latin American e-commerce, a GLP-1 weight loss drug maker trading at less than 10 times earnings with a big dividend, a software company making government more efficient, and a speculative biotech stock with an FDA decision coming in November. Plus, he explains how he uses a trailing stop to let profits run and cut losses short.

Chapters 0:00 Introduction 1:57 The Midterm Miracle 5:31 Stock 1 10:11 Stock 2 15:20 Stocks 3 18:30 Stock 4 21:36 How to Use a Trailing Stop

View Bridget's Buys here: https://www.marketbeat.com/bridget

📲 Text 'YouTube' to 68285 for FREE SMS breaking news alerts on top stocks.

For YouTube sponsorships, brand partnerships and advertising, send an email to: [email protected]

DISCLAIMER: MarketBeat's videos are for educational and informational purposes only and do not constitute financial, legal, or tax advice. We are not registered investment advisers, and nothing herein is a recommendation to buy, sell, or hold any security or strategy. Investing involves risk—including the potential loss of principal—so always perform your own due diligence and consult a licensed professional before acting. All opinions are those of the presenters and may change without notice. Presenters and MarketBeat personnel may own or trade the securities discussed. Past performance is not indicative of future results; any examples or case studies shown are illustrative and not typical. Some links or promotions mentioned may be affiliate partnerships that compensate MarketBeat at no additional cost to you. MarketBeat and its representatives accept no liability for any losses arising from reliance on this content.